Financial Data and Key Metrics Changes - The company reported a decline in sales and brand partner productivity leading up to the global convention in August, but recent activity has shown improvement [4][7] - Year-to-date sales growth for the direct-to-consumer business, HYA, is at 26%, indicating a positive trajectory despite challenges in the third quarter [10] - RiseBAR reported record third-quarter net sales with year-to-date net sales increasing by 169% [12] Business Line Data and Key Metrics Changes - The enhanced compensation plan has led to increased engagement and excitement among brand partners, contributing to improved sales activity and leader productivity [5][7] - The company has seen an increase in inventories due to new product introductions and investments in inventory locations to support tariff mitigation [8] - HYA has faced challenges in top-line growth but is expected to bounce back as operational efficiencies are realized [10][29] Market Data and Key Metrics Changes - The Americas and Europe regions performed relatively better than other regions, attributed to the maturity of these markets and the impact of the RiseBAR performance [25][26] - The children's vitamin market, where HYA operates, is competitive, but HYA has been gaining market share through its direct-to-consumer model [42] Company Strategy and Development Direction - The company is focused on a comprehensive commercial strategy that includes an enhanced compensation plan, product innovation, and improved tools for brand partners [5][6] - There is a commitment to diversification, with plans to explore mergers and acquisitions to strengthen the portfolio [46][47] - A global cost reduction process has been initiated, including workforce rightsizing, to support a more agile organization [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the direct selling business and the diversification strategy with HYA and RiseBAR [13][14] - The company is optimistic about the future, citing renewed excitement among brand partners and positive early indicators from the new compensation plan [4][7] Other Important Information - The company anticipates a one-time charge of $4.7 million in the fourth quarter related to the global cost reduction process [13] - The management is focused on ensuring that the new compensation plan is well understood and embraced by brand partners globally [27] Q&A Session Summary Question: Can you walk us through the trajectory of your business trends from July through October? - Management noted promising trends from the new compensation plan launched in July, with increased engagement and excitement observed in September and early October [17][19] Question: Why did the Americas and Europe region perform better? - The performance was influenced by the global convention and the contribution from RiseBAR, which is a smaller percentage of overall sales [25][26] Question: What incentives are planned for the fourth quarter? - The company plans to provide strategic incentives for brand partners, which are expected to carry over into Q1 of the following year [27] Question: What are the reasons for the decline in active customer count for HYA? - Management indicated that the decline was due to changes in marketing algorithms on platforms like Meta, but they expect a rebound as they adapt [28][29] Question: How will the rightsizing of the organization impact annualized operating cost savings? - Management stated that they are still early in the process and will provide more details on cost savings in February [30][31] Question: Are there opportunities for further acquisitions in the DTC space? - The company is committed to diversification and will explore opportunities for mergers and acquisitions to strengthen its portfolio [46][47]

Financial Data and Key Metrics Changes - The company reported a decline in sales and brand partner productivity leading up to the global convention in August, but recent activity has shown improvement [4][6] - An increase in inventories was noted, attributed to new product introductions and investments in inventory locations for tariff mitigation [8] - The company expects to incur a one-time charge of $4.7 million in the fourth quarter due to a global cost reduction process [12] Business Line Data and Key Metrics Changes - Hiya Health experienced a 26% year-to-date sales growth despite challenges in the third quarter, with significant progress in integration initiatives [9] - RiseBar reported record third quarter net sales, with year-to-date net sales increasing by 169% [10][11] - The company is investing additional resources in Hiya Health and RiseBar to capitalize on current momentum and drive long-term growth [11] Market Data and Key Metrics Changes - The Americas and Europe regions performed relatively better than other regions, partly due to the maturity of these markets and the impact of the RiseBar performance [21] - The direct selling business has struggled over the past few years, but recent changes in compensation plans are expected to improve engagement and sales [31] Company Strategy and Development Direction - The company is focused on a comprehensive commercial strategy that includes an enhanced compensation plan, product innovation, and improved tools for brand partners [4][5] - Diversification remains a key strategy, with ongoing investments in Hiya Health and RiseBar, as well as potential M&A opportunities [35][36] - The company aims to create lasting value across its portfolio while adapting to a competitive landscape [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the direct selling business and the diversification strategy [12] - The company is optimistic about the future, particularly with the growth of Hiya Health in the children's health market and RiseBar in the healthy foods market [12] - Management acknowledged the challenges in the direct selling industry but believes recent changes will position the company for future success [31] Other Important Information - The company has initiated a global cost reduction process, including a right-sizing of the workforce, to prioritize strategic initiatives and improve efficiency [11][12] - Management highlighted the importance of simplicity and early success in the new compensation plan to attract younger demographics [5][6] Q&A Session Summary Question: Can you walk us through the trajectory of your business trends from July through October? - Management noted promising trends from the new compensation plan launched in July, with increased engagement and excitement observed in September and early October [17][19] Question: Can you discuss the incentives planned for the fourth quarter? - The company plans to provide strategic incentives for brand partners in the fourth quarter, which may carry over into early 2026 [22] Question: What are the reasons for the decline in active customer count for Hiya Health? - Management expressed confidence in Hiya Health's growth despite recent slowdowns, attributing challenges to changes in marketing algorithms [23] Question: How should we think about the level of annualized operating cost savings from the right-sizing process? - Management indicated that it is early in the process and will provide more details on cost savings in February [24] Question: Are you seeing any slowdown in consumer purchases related to VMS or wellness? - The company acknowledged struggles in the direct selling business but believes recent offerings will help improve performance [31] Question: Is there an opportunity to acquire more DTC businesses? - Management confirmed that diversification and potential M&A opportunities are part of the future strategy [35]

分组1 - USANA Health Sciences reported a quarterly loss of $0.15 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.56 per share a year ago [1] - The company posted revenues of $213.67 million for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.1%, and showing an increase from $200.22 million year-over-year [2] - USANA Health shares have declined approximately 41.4% since the beginning of the year, contrasting with the S&P 500's gain of 14.5% [3] 分组2 - The earnings outlook for USANA Health is uncertain, with current consensus EPS estimates at $0.37 for the upcoming quarter and $1.70 for the current fiscal year [7] - The Medical - Drugs industry, to which USANA belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

Core Viewpoint - USANA Health Sciences, Inc. has updated the timing for the release of its third quarter 2025 financial results, moving it from October 21, 2025, to October 22, 2025, after market close [1] Financial Results Announcement - The company will report its third quarter 2025 financial results after the market closes on October 22, 2025, instead of the previously scheduled date of October 21, 2025 [1]

Core Insights - USANA's Vitamin D supplement has received the ConsumerLab.com Seal of Approval, indicating its purity, potency, and scientific precision [1][2] - Approximately 42% of adults in the U.S. are vitamin D deficient, highlighting the importance of reliable supplements in the market [1] - The supplement contains 2000 IU of vitamin D3 per tablet, exceeding current recommendations by more than four times [7] Product Quality and Testing - The approval from ConsumerLab.com reflects USANA's commitment to transparency, quality, and precision in its products [2][3] - The Vitamin D supplement underwent rigorous testing for potency, purity, and label accuracy, ensuring it delivers 100% of the claimed amounts of vitamin D3 and vitamin K [2] - USANA's internal standards align with the benchmarks required for the Seal of Approval, emphasizing the company's dedication to high-quality products [2][3] Scientific Backing and Benefits - The Vitamin D supplement is designed to support bone strength, immune defense, and nutrient absorption [3] - USANA continues to invest in research, manufacturing, and testing protocols to maintain its position as an industry leader in nutritional science [4] Company Overview - USANA has been providing premium-quality nutrition and lifestyle products for over 30 years, with a focus on empowering healthier living [6] - The company manufactures its award-winning supplements in an FDA-registered facility, ensuring high standards of quality [6]

Core Insights - USANA Health Sciences Inc. reported preliminary earnings for Q3 2025, leading to an initial share price decline of approximately 11% [1] Financial Performance - The company is currently undergoing a transitional period, which has affected investor sentiment [1] Company Background - USANA operates in the health sciences sector, focusing on nutritional products and dietary supplements [1]

Company Performance - Apogee Enterprises Inc. reported better-than-expected second-quarter financial results, with shares gaining 1.4% to $42.00 in after-hours trading [2] - Levi Strauss & Co. reported third-quarter earnings of 34 cents per share, exceeding the analyst consensus estimate of 31 cents per share, and quarterly sales of $1.543 billion, surpassing the estimate of $1.501 billion; however, shares fell 7.7% to $22.65 in after-hours trading [2] - VolitionRX Ltd. announced a public offering of common stock and common stock warrants, leading to a 20% dip in shares to $0.48 in after-hours trading [2] - USANA Health Sciences Inc. reported preliminary third-quarter results with an adjusted loss of 15 cents per share and sales of $214.00 million, resulting in an 11.4% decline in shares to $23.26 in after-hours trading [2] - Nurix Therapeutics Inc. reported worse-than-expected third-quarter financial results, causing shares to fall 5.7% to $10.24 in after-hours trading [2]

Preliminary Third Quarter 2025 Results Overview [Summary of Financial Performance](index=1&type=section&id=Summary%20of%20Financial%20Performance) USANA reported preliminary Q3 2025 net sales of $214 million, but a net loss of ($6.5) million and diluted EPS of ($0.36), with a 471% effective tax rate Q3 2025 Preliminary Financial Highlights vs Q3 2024 | Metric | Q3 2025 Preliminary | Q3 2024 | Change (YoY) | | :------------------------ | :-------------------- | :-------------- | :----------- | | Net sales | $214 million | $200 million | +$14 million | | Earnings from operations | $1.2 million | $15.6 million | -$14.4 million | | Operating Margin | 0.6% | 7.8% | -7.2% pts | | Net (loss) earnings | ($6.5) million | $10.6 million | -$17.1 million | | Diluted EPS | ($0.36) | $0.56 | -$0.92 | | Effective income tax rate | 471% | 43% | +428% pts | | Adjusted Diluted EPS | ($0.15) | $0.56 | -$0.71 | | Adjusted EBITDA | $13.8 million | $24.6 million | -$10.8 million | - The effective income tax rate for Q3 2025 significantly increased to **471%** from **43%** in Q3 2024, primarily due to lower than expected earnings coupled with the concentration of operating and administrative expenses in the United States[4](index=4&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) [Management Commentary on Performance and Strategy](index=1&type=section&id=Management%20Commentary%20on%20Performance%20and%20Strategy) Management noted Q3 operating results were below expectations due to softer sales and Brand Partner productivity, but remains confident in long-term strategy - Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of the enhanced Brand Partner compensation plan, and softer sales for Hiya due to lower customer acquisition rates[2](index=2&type=chunk) - Despite short-term challenges, the enhanced compensation plan is viewed as a strategic move for long-term success, with encouraging Brand Partner response and recent pickup in sales activity. Hiya is still expected to generate **double-digit sales growth for 2025**[2](index=2&type=chunk)[3](index=3&type=chunk) [CFO's Commentary and Outlook](index=2&type=section&id=CFO%27s%20Commentary%20and%20Outlook) CFO highlighted Q3 profitability challenges from softer sales and increased tax rate, expecting full-year sales at the lower end of outlook and EPS below range - Profitability challenges in Q3 included softer sales, meaningful investments in the enhanced Brand Partner compensation plan, and a disproportionate increase in the estimated annual effective income tax rate from **45% to 65%** (**471% for Q3 2025**)[4](index=4&type=chunk) - For the full year, sales are expected to be at or near the lower end of the previously issued outlook range, and earnings per share are expected to be below the range, starting from a lower base of active customer counts in Q4. The company plans to align costs with operating performance to achieve a meaningfully lower tax rate in future years[5](index=5&type=chunk) [Upcoming Earnings Release and Conference Call](index=3&type=section&id=Upcoming%20Earnings%20Release%20and%20Conference%20Call) Final Q3 results are scheduled for release on October 21, 2025, with a conference call for analysts on October 22, 2025 - Final results for the third quarter are expected to be released after the close of market on **Tuesday, October 21, 2025**[7](index=7&type=chunk) - A conference call to discuss the announcement with analysts and institutional investors will be held on **Wednesday, October 22, 2025, at 11:00 a.m. Eastern Time**[7](index=7&type=chunk) Non-GAAP Financial Measures [Definition and Purpose](index=3&type=section&id=Definition%20and%20Purpose) This section defines non-GAAP measures like Adjusted EBITDA and Adjusted diluted EPS, used by management for internal assessment but not as GAAP substitutes - Adjusted EBITDA and Adjusted diluted EPS are non-GAAP financial measures used by management to internally reflect how the Company measures the business[9](index=9&type=chunk)[10](index=10&type=chunk)[15](index=15&type=chunk) - Non-GAAP financial measures have limitations, lack standardized meaning, and should not be considered in isolation from, or as a substitute for, GAAP financial information[16](index=16&type=chunk) [Reconciliation of Net (Loss) Earnings to Adjusted EBITDA](index=5&type=section&id=Reconciliation%20of%20Net%20%28Loss%29%20Earnings%20to%20Adjusted%20EBITDA) This section provides a reconciliation of GAAP Net (loss) earnings to Adjusted EBITDA, detailing adjustments for taxes, interest, depreciation, amortization, and acquisition costs Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands USD) | | Quarter Ended | | Nine Months Ended | | | --- | --- | --- | --- | --- | | | Q3 2025 | Q3 2024 | YTD Sep-25 | YTD Sep-24 | | | September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | | Net (loss) earnings attributable to USANA (GAAP) | $ (6,522) | $ 10,607 | $ 12,535 | $ 37,576 | | Net (loss) earnings attributable to noncontrolling interest | (140) | - | 537 | - | | Net (loss) earnings | $ (6,662) | $ 10,607 | $ 13,072 | $ 37,576 | | Adjustments: | | | | | | Income taxes | 8,456 | 8,001 | 24,278 | 28,346 | | Interest (income) expense | (529) | (3,093) | (1,201) | (8,429) | | Depreciation and amortization | 5,112 | 5,559 | 16,050 | 16,345 | | Amortization of intangible assets - Hiya | 4,455 | - | 13,366 | - | | Earnings before interest, taxes, depreciation, and amortization (EBITDA) | 10,832 | 21,074 | 65,565 | 73,838 | | Add EBITDA adjustments: | | | | | | Non-cash share-based compensation | 3,576 | 3,542 | 10,078 | 10,945 | | Transaction, integration and transition costs - Hiya | 179 | - | 871 | - | | Inventory step-up - Hiya | - | - | 1,126 | - | | Consolidated adjusted EBITDA | 14,587 | 24,616 | 77,640 | 84,783 | | Less: Adjusted EBITDA attributable to noncontrolling interest | (804) | - | (3,604) | - | | Adjusted EBITDA attributable to USANA | $ 13,783 | $ 24,616 | $ 74,036 | $ 84,783 | [Reconciliation of Diluted (Loss) Earnings Per Share to Adjusted Diluted (Loss) Earnings Per Share](index=6&type=section&id=Reconciliation%20of%20Diluted%20%28Loss%29%20Earnings%20Per%20Share%20to%20Adjusted%20Diluted%20%28Loss%29%20Earnings%20Per%20Share) This section reconciles GAAP Diluted (Loss) EPS to Adjusted Diluted (Loss) EPS, detailing adjustments for Hiya acquisition costs, intangible asset amortization, and tax effects Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP) (in thousands USD, except per share data) | | Quarter Ended | | | Nine Months Ended | | --- | --- | --- | --- | --- | | | September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 | | Net (loss) earnings attributable to USANA (GAAP) | $ (6,522) | $ 10,607 | $ 12,535 | $ 37,576 | | Earnings (loss) per common share - Diluted (GAAP) | $ (0.36) | $ 0.56 | $ 0.67 | $ 1.96 | | Weighted average common shares outstanding - Diluted | 18,293 | 19,083 | 18,671 | 19,181 | | Adjustment to net (loss) earnings: | | | | | | Transaction, integration and transition costs - Hiya | $ 179 | $ - | $ 871 | $ - | | Inventory step-up - Hiya | - | - | 1,126 | - | | Amortization of intangible assets - Hiya | 4,455 | - | 13,366 | - | | Adjustments to net (loss) earnings attributable to noncontrolling interest | (941) | - | (3,066) | - | | Income tax effect of adjustments to net (loss) earnings | - | - | (4) | - | | Adjusted net (loss) earnings attributable to USANA | $ (2,829) | $ 10,607 | $ 24,828 | $ 37,576 | | Adjusted (loss) earnings per common share - Diluted | $ (0.15) | $ 0.56 | $ 1.33 | $ 1.96 | | Weighted average common shares outstanding - Diluted | 18,293 | 19,083 | 18,671 | 19,181 | Company Information [About USANA Health Sciences](index=8&type=section&id=About%20USANA%20Health%20Sciences) USANA develops and manufactures nutritional supplements and personal care products, sold directly, and holds a **78.8%** stake in Hiya Health Products - USANA develops and manufactures high-quality nutritional supplements, functional foods, and personal care products, sold directly to Brand Partners and Preferred Customers in various global markets[21](index=21&type=chunk) - USANA owns a **78.8%** controlling ownership stake in Hiya Health Products, a children's health and wellness company[21](index=21&type=chunk) [Safe Harbor Statement](index=7&type=section&id=Safe%20Harbor%20Statement) This statement clarifies that the press release contains forward-looking statements subject to risks and uncertainties, including economic conditions and regulatory changes - The press release contains forward-looking statements based on current plans, expectations, estimates, forecasts, and projections, which involve a number of risks and uncertainties that could cause actual results to differ materially[19](index=19&type=chunk) - Key risks include global economic conditions, reliance on independent Brand Partners, effectiveness of compensation plans, governmental regulation, geopolitical relations, data privacy, and the integration of the Hiya acquisition[19](index=19&type=chunk)[20](index=20&type=chunk) [Investor and Media Contacts](index=8&type=section&id=Investor%20and%20Media%20Contacts) Contact information for investor relations and media inquiries is provided - Investor Relations Contact: **Andrew Masuda**, (801) 954-7201, investor.relations@usanainc.com[22](index=22&type=chunk) - Media Contact: **Sarah Searle**, (801) 954-7626, media@usanainc.com[22](index=22&type=chunk)

Core Insights - Dr. Kathryn Armstrong, Chief Scientific Officer of USANA, has been awarded the Women Tech Award by the Women Tech Council of Utah, highlighting her significant contributions to the technology sector [1][2][4] - The Women Tech Award aims to enhance the visibility of women in technology, celebrating those who inspire innovation and advancement within the industry [2][4] - This recognition reflects USANA's commitment to scientific innovation and empowering women in the workplace, reinforcing the company's dedication to health and wellness [4][6] Company Overview - USANA has been providing premium-quality nutrition and lifestyle products for over 30 years, including award-winning supplements and skincare products [6] - The company operates an FDA-registered facility, ensuring high standards in product manufacturing [6] - USANA is focused on empowering individuals to lead healthier lives through its innovative products and scientific advancements [6] Leadership and Team - Dr. Armstrong leads a team of over 150 professionals across various departments, including product development, regulatory affairs, and quality control [5] - She joined USANA in 2024, bringing 18 years of experience from globally recognized corporations, along with a strong academic background in Chemistry and Biochemistry [4][5]